HIMS Stock Analysis: Buy, Sell, or Hold?
HIMS - Hims & Hers Health, Inc.
$20.74
1.96 (10.41%)
▲
5d:
-2.83%
30d:
+25.82%
90d:
-39.19%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 04, 2026
Smart Money Accumulation
HIMS is down 5.5% this week, but smart money is accumulating calls. Top strike: $20 2026-04-17 with 1,535 OI. Call ratio: 67% View Scanner →
Strength: 4.5/10
Get Alerted When HIMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HIMS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: HIMS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$30.46
Based on 14.0% avg growth
INTRINSIC VALUE TODAY
$18.92
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HIMS is currently trading at $20.74, which is considered fair relative to its 30-day fair value range of $16.15 to $23.55. From a valuation perspective, the stock is trading at a discount (Forward PE: 29.4) compared to its historical average (41.9). Remarkably, the market is currently pricing in an annual earnings decline of 11.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, HIMS is in a strong downtrend. Immediate support is located at $18.62, while resistance sits at $25.04. The stock is showing strong short-term momentum, up 10.4% recently.
Market Sentiment: HIMS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $24.15 (+28.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HIMS is in a strong downtrend. Immediate support is located at $18.62, while resistance sits at $25.04. The stock is showing strong short-term momentum, up 10.4% recently.
Market Sentiment: HIMS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $24.15 (+28.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$16.15 -
$23.55
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
Protect Your Profits
Holding HIMS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.4%)
- BULLISH: Trading 28.6% below Wall St target ($24.15)
Fair Price Analysis
30-Day Fair Range
$16.15 -
$23.55
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$18.62
Resistance Level
$25.04
Current Trend
Strong Downtrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
29.39
Wall Street Target
$24.15
(+28.6%)
Revenue Growth (YoY)
28.4%
Earnings Growth (YoY)
-17.4%
Profit Margin
5.5%
Valuation Discount vs History
-11.1% cheaper
PE vs Historical
29.4 vs 41.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.1%
(market-implied from PE analysis)
1-Year Target
$16.90
(-10%)
2-Year Target
$15.21
(-19%)
3-Year Target
$13.69
(-27%)
3-Yr Target (if PE normalizes)
(PE: 29→42)
$19.52
(+4%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 29.4, Growth: 24.0%)
$35.77
(+91%)
Base:
(SPY PE: 22.4, Growth: 24.0%)
$27.20
(+45%)
Bear:
(PE: 19.0, Growth: 24.0%)
$23.12
(+23%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (43x PE), but valuation improves significantly next year (29x PE) as earnings recover.
Trailing PE: 43.18 | Current EPS (TTM): $0.51
Bull Case
$30.96
(+38%)
Analyst growth 27.8%, PE expands to 47.5
Base Case
$28.14
(+25%)
Market implied 27.8%, PE stable at 43.2
Bear Case
$14.97
(-33%)
Severe decline -20.0%, PE contracts to 36.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 29.4 to 41.9
Stabilization Target:
$26.77
(+42.6%)
PE Expansion Potential:
+42.6%
Share & Embed Analysis
Last updated: March 31, 2026 1:35 PM ET
Data refreshes hourly during market hours. Next update: 2:35 PM
Data refreshes hourly during market hours. Next update: 2:35 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HIMS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Chi
SELL
97289 shares
2026-03-17
Soleil Boughton
SELL
4812 shares
2026-03-17
Irene Becklund
SELL
5529 shares
2026-03-17
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 63 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
Advanced HIMS Option Strategies
Professional options setups generated by AI based on today's HIMS price and gamma walls.
